
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Lux... Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The company has two clinical-stage programs and a second program that is discovery-stage and partnered with another company. Luxeptinib, its panFMS-like tyrosine kinase 3 / pan-Bruton's tyrosine kinase inhibitor, is enrolling patients in a Phase 1, multicenter, open label, dose-escalation study with expansions to assess the safety, tolerability, PK, and preliminary efficacy of CG-806 in patients with chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL). HM43239 is an oral potent myeloid kinome inhibitor, targeting a constellation of kinases operative in myeloid malignancies. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 1.71 | 1.71 | 1.71 | 0 | 0 | CS |
4 | -1.98 | -53.6585365854 | 3.69 | 3.9799 | 1.35 | 48322 | 2.3123459 | CS |
12 | 1.5089 | 750.323222277 | 0.2011 | 3.9799 | 0.11 | 6199112 | 0.21413783 | CS |
26 | 1.3515 | 376.987447699 | 0.3585 | 3.9799 | 0.11 | 6252306 | 0.2374685 | CS |
52 | 0.32 | 23.0215827338 | 1.39 | 3.9799 | 0.11 | 3252336 | 0.24852865 | CS |
156 | -18.84 | -91.6788321168 | 20.55 | 20.55 | 0.11 | 1208392 | 1.26072261 | CS |
260 | -90.24 | -98.1402936378 | 91.95 | 138 | 0.11 | 1292692 | 31.84015463 | CS |
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관